Gonorrhea
Gonococcal Infections
การวินิจฉัย
Gram stain : diplococci ,intracellular
การรักษา
มียาให้เลือกรักษาหลายแบบ
Ceftriazone 250 mg im only one dose
or Cefixim 400 mg oral only one dose
ต้องรักษาคู่นอนด้วย และ ต้องรักษา non-GC ด้วย
Doxycyclin (100mg ) 1x2 oral pc 14 days CDC 7 วัน
or Roxithromycin 1x2 oral pc 14 days
or Erythromycin (500) 1x4 oral pc 14 days
......................................................................
Gonococcal Infections in Adolescents and Adults
การติดเชื้อในผู้ชายมักแสดงอาการชัดเจน จึงมักได้รับการรักษาจนหาย
แต่ในผู้หญิง อาการไม่ชัดเจนจนกระทั่งเกิดเป็น PID ขึ้นมา ก่อเกิดปัญหา tubal scarring เป็น infetility , ectopic pregnancy ได้In the United .
Dual Therapy for Gonococcal and Chlamydial Infections
Patients infected with N. gonorrhoeae often are coinfected with C. trachomatis; this finding led to the recommendation that
patients treated for gonococcal infection also be treated routinely with a regimen effective against uncomplicated genital C.
trachomatis infection.
Quinolone-resistant N. gonorrhoeae (QRNG)
QRNG continues to spread, making the treatment of gonorrhea with quinolones inadvisable in many areas. QRNG is common in
parts of Asia and the Pacific.
Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum
Recommended Regimens
Cefixime 400 mg orally in a single dose,
OR
Ceftriaxone 125 mg IM in a single dose,
OR
Ciprofloxacin 500 mg orally in a single dose,§§
OR
Ofloxacin 400 mg orally in a single dose,§§
OR
Levofloxacin 250 mg orally in a single dose,§§
PLUS,
IF CHLAMYDIAL INFECTION IS NOT RULED OUT
Azithromycin 1 g orally in a single dose
OR
Doxycycline 100 mg orally twice a day for 7 days.
§§ Quinolones should not be used for infections acquired in Asia or the Pacific, including Hawaii. In addition, use of quinolones
is probably inadvisable for treating infections acquired in California and in other areas with increased prevalence of quinolone
resistance.
Cefixime has an antimicrobial spectrum similar to that of ceftriaxone, but the 400-mg oral dose does not provide as high nor as
sustained a bactericidal level as that provided by the 125-mg dose of ceftriaxone. In published clinical trials, the 400-mg dose
cured 97.4% of uncomplicated urogenital and anorectal gonococcal infections (50). The advantage of cefixime is that it can be
administered orally.
Ceftriaxone in a single injection of 125 mg provides sustained, high bactericidal levels in the blood. Extensive clinical experience
indicates that ceftriaxone is safe and effective for the treatment of uncomplicated gonorrhea at all anatomic sites, curing 99.1%
of uncomplicated urogenital and anorectal infections in published clinical trials (50).
Ciprofloxacin is effective against most strains of N. gonorrhoeae in the United States (excluding Hawaii). At a dose of 500 mg,
ciprofloxacin provides sustained bactericidal levels in the blood; in published clinical trials, it has cured 99.8% of uncomplicated
urogenital and anorectal infections. Ciprofloxacin is safe, inexpensive, and can be administered orally.
Ofloxacin also is effective against most strains of N. gonorrhoeae in the United States (excluding Hawaii), and it has favorable
pharmacokinetics. The 400-mg oral dose has been effective for treatment of uncomplicated urogenital and anorectal infections,
curing 98.6% of infections in published clinical trials. Levofloxacin, the active l-isomer of ofloxacin, can be used in place of
ofloxacin as a single dose of 250 mg.
Alternative Regimens
Spectinomycin 2 g in a single, IM dose. Spectinomycin is expensive and must be injected; however, it has been effective in
published clinical trials, curing 98.2% of uncomplicated urogenital and anorectal gonococcal infections. Spectinomycin is useful for
treatment of patients who cannot tolerate cephalosporins and quinolones.
Single-dose cephalosporin regimens (other than ceftriaxone 125 mg IM and cefixime 400 mg orally) that are safe and highly
effective against uncomplicated urogenital and anorectal gonococcal infections include ceftizoxime (500 mg, administered IM),
cefoxitin (2 g, administered IM with probenecid 1 g orally), and cefotaxime (500 mg, administered IM). None of the injectable
cephalosporins offer any advantage over ceftriaxone.
Single-dose quinolone regimens include gatifloxacin 400 mg orally, norfloxacin 800 mg orally, and lomefloxacin 400 mg orally.
These regimens appear to be safe and effective for the treatment of uncomplicated gonorrhea, but data regarding their use are
limited. None of the regimens appear to offer any advantage over ciprofloxacin at a dose of 500 mg, ofloxacin at 400 mg, or
levofloxacin at 250 mg.
Many other antimicrobials are active against N. gonorrhoeae, but none have substantial advantages over the recommended
regimens. Azithromycin 2 g orally is effective against uncomplicated gonococcal infection, but it is expensive and causes
gastrointestinal distress, so it is not recommended for treatment of gonorrhea. At an oral dose of 1 g, azithromycin is
insufficiently effective and is not recommended.
Uncomplicated Gonococcal Infections of the Pharynx
Gonococcal infections of the pharynx are more difficult to eradicate than infections at urogenital and anorectal sites. Few
antimicrobial regimens can reliably cure >90% of infections.
Although chlamydial coinfection of the pharynx is unusual, coinfection at genital sites sometimes occurs. Therefore, treatment for
both gonorrhea and chlamydia is recommended.
Recommended Regimens
Ceftriaxone 125 mg IM in a single dose
OR
Ciprofloxacin 500 mg orally in a single dose§§
PLUS,
IF CHLAMYDIAL INFECTION IS NOT RULED OUT
Azithromycin 1 g orally in a single dose
OR
Doxycycline 100 mg orally twice daily for 7 days.
Follow-Up
Patients who have uncomplicated gonorrhea and who are treated with any of the recommended regimens need not return for a
test to confirm that they are cured. Patients who have symptoms that persist after treatment should be evaluated by culture for
N. gonorrhoeae, and any gonococci isolated should be tested for antimicrobial susceptibility. Infections identified after treatment
with one of the recommended regimens usually result from reinfection rather than treatment failure, indicating a need for
improved patient education and referral of sex partners. Persistent urethritis, cervicitis, or proctitis also may be caused by C.
trachomatis and other organisms.
Management of Sex Partners
Patients should be instructed to refer their sex partners for evaluation and treatment. All sex partners of patients who have N.
gonorrhoeae infection should be evaluated and treated for N. gonorrhoeae and C. trachomatis infections if their last sexual
contact with the patient was within 60 days before onset of symptoms or diagnosis of infection in the patient. If a patient's last
sexual intercourse was >60 days before onset of symptoms or diagnosis, the patient's most recent sex partner should be
treated. Patients should be instructed to avoid sexual intercourse until therapy is completed and until they and their sex partners
no longer have symptoms.
Special Considerations
Allergy, Intolerance, and Adverse Reactions
Persons who cannot tolerate cephalosporins or quinolones should be treated with spectinomycin. Because spectinomycin is
unreliable (i.e., only 52% effective) against pharyngeal infections, patients who have suspected or known pharyngeal infection
should have a pharyngeal culture evaluated 3--5 days after treatment to verify eradication of infection.
Pregnancy
Pregnant women should not be treated with quinolones or tetracyclines. Those infected with N. gonorrhoeae should be treated
with a recommended or alternate cephalosporin. Women who cannot tolerate a cephalosporin should be administered a single,
2-g dose of spectinomycin IM. Either erythromycin or amoxicillin is recommended for treatment of presumptive or diagnosed C.
trachomatis infection during pregnancy (see Chlamydial Infection).
Administration of Quinolones to Adolescents
Fluoroquinolones have not been recommended for persons aged <18 years because studies have indicated that they can
damage articular cartilage in some young animals. However, no joint damage attributable to quinolone therapy has been
observed in children treated with prolonged ciprofloxacin regimens. Thus, children who weigh >45 kg can be treated with any
regimen recommended for adults (See Gonococcal Infections).
HIV Infection
Patients who have gonococcal infection and also are infected with HIV should receive the same treatment regimen as those
who are HIV-negative.
Gonococcal Conjunctivitis
In the only published study of the treatment of gonococcal conjunctivitis among U.S. adults, all 12 study participants responded
to a single 1-g IM injection of ceftriaxone (51). The following recommendations reflect the opinions of consultants knowledgeable
in the field of STDs.
Recommended Regimen
Ceftriaxone 1 g IM in a single dose.
NOTE: Consider lavage of the infected eye with saline solution once.
Management of Sex Partners
Patients should be instructed to refer their sex partners for evaluation and treatment (see Gonococcal Infection, Management of
Sex Partners).
Disseminated Gonococcal Infection (DGI)
DGI results from gonococcal bacteremia. DGI often results in petechial or pustular acral skin lesions, asymmetrical arthralgia,
tenosynovitis, or septic arthritis. The infection is complicated occasionally by perihepatitis and rarely by endocarditis or meningitis.
Some strains of N. gonorrhoeae that cause DGI may cause minimal genital inflammation.
No recent studies of the treatment of DGI among U.S. adults have been published. The following recommendations reflect the
opinions of consultants knowledgeable in the STD field. No treatment failures have been reported using the following
recommended regimen.
Treatment
Hospitalization is recommended for initial therapy, especially for patients who may not comply with treatment, for those in whom
diagnosis is uncertain, and for those who have purulent synovial effusions or other complications. Patients should be examined
for clinical evidence of endocarditis and meningitis. Patients treated for DGI should be treated presumptively for concurrent C.
trachomatis infection, unless appropriate testing excludes this infection.
Recommended Regimen
Ceftriaxone 1 g IM or IV every 24 hours.
Alternative Regimens
Cefotaxime 1 g IV every 8 hours,
OR
Ceftizoxime 1 g IV every 8 hours,
OR
Ciprofloxacin 400 mg IV every 12 hours,§§
OR
Ofloxacin 400 mg IV every 12 hours,§§
OR
Levofloxacin 250 mg IV daily,§§
OR
Spectinomycin 2 g IM every 12 hours.
All of the preceding regimens should be continued for 24--48 hours after improvement begins, at which time therapy may be
switched to one of the following regimens to complete at least 1 week of antimicrobial therapy.
Cefixime 400 mg orally twice daily,
OR
Ciprofloxacin 500 mg orally twice daily,§§
OR
Ofloxacin 400 mg orally twice daily,§§
OR
Levofloxacin 500 mg orally once daily.§§
Management of Sex Partners
Gonococcal infection often is asymptomatic in sex partners of patients who have DGI. As with uncomplicated gonococcal
infections, patients should be instructed to refer their sex partners for evaluation and treatment (see Gonococcal Infection,
Management of Sex Partners).
Gonococcal Meningitis and Endocarditis
Recommended Regimen
Ceftriaxone 1--2 g IV every 12 hours.
Therapy for meningitis should be continued for 10--14 days; therapy for endocarditis should be continued for at least 4 weeks.
Treatment of complicated DGI should be undertaken in consultation with a specialist.
Management of Sex Partners
Patients should be instructed to refer their sex partners for evaluation and treatment (see Gonococcal Infection, Management of
Sex Partners).
Gonococcal Infections Among Infants
Gonococcal infection among infants usually results from exposure to infected cervical exudate at birth. It is usually an acute
illness that becomes manifest 2--5 days after birth. The prevalence of infection among infants depends on the prevalence of
infection among pregnant women, on whether pregnant women are screened for gonorrhea, and on whether newborns receive
ophthalmia prophylaxis.
The most severe manifestations of N. gonorrhoeae infection in newborns are ophthalmia neonatorum and sepsis, including
arthritis and meningitis. Less severe manifestations include rhinitis, vaginitis, urethritis, and inflammation at sites of fetal
monitoring.
Ophthalmia Neonatorum Caused by N. gonorrhoeae
In the United States, although N. gonorrhoeae causes ophthalmia neonatorum less often than C. trachomatis and nonsexually
transmitted agents, identifying and treating this infection is especially important because ophthalmia neonatorum can result in
perforation of the globe of the eye and blindness.
Diagnostic Considerations
Infants at increased risk for gonococcal ophthalmia are those who do not receive ophthalmia prophylaxis and those whose
mothers have had no prenatal care or whose mothers have a history of STDs or substance abuse. Gonococcal ophthalmia is
strongly suspected when intracellular Gram-negative diplococci are identified in conjunctival exudate, justifying presumptive
treatment for gonorrhea after appropriate cultures for N. gonorrhoeae are obtained. Appropriate chlamydial testing should be
done simultaneously. Presumptive treatment for N. gonorrhoeae may be indicated for newborns who are at increased risk for
gonococcal ophthalmia and who have conjunctivitis but do not have gonococci in a Gram-stained smear of conjunctival exudate.
In all cases of neonatal conjunctivitis, conjunctival exudate should be cultured for N. gonorrhoeae and tested for antibiotic
susceptibility before a definitive diagnosis is made. A definitive diagnosis is important because of the public health and social
consequences of a diagnosis of gonorrhea. Nongonococcal causes of neonatal ophthalmia include Moraxella catarrhalis and
other Neisseria species that are indistinguishable from N. gonorrhoeae on Gram-stained smear but can be differentiated in the
microbiology laboratory.
Recommended Regimen
Ceftriaxone 25--50 mg/kg IV or IM in a single dose, not to exceed 125 mg.
NOTE: Topical antibiotic therapy alone is inadequate and is unnecessary if systemic treatment is administered.
Other Management Considerations
Simultaneous infection with C. trachomatis should be considered when a patient does not improve after treatment. Both mother
and infant should be tested for chlamydial infection at the same time that gonorrhea testing is conducted (see Ophthalmia
Neonatorum Caused by C. trachomatis). Ceftriaxone should be administered cautiously to hyperbilirubinemic infants, especially
those born prematurely.
Follow-Up
Infants who have gonococcal ophthalmia should be hospitalized and evaluated for signs of disseminated infection (e.g., sepsis,
arthritis, and meningitis). One dose of ceftriaxone is adequate therapy for gonococcal conjunctivitis.
Management of Mothers and Their Sex Partners
The mothers of infants who have gonococcal infection and the mothers' sex partners should be evaluated and treated according
to the recommendations for treating gonococcal infections in adults (see Gonococcal Infection in Adolescents and Adults).
Disseminated Gonococcal Infection and Gonococcal Scalp Abscesses in Newborns
Sepsis, arthritis, and meningitis (or any combination of these conditions) are rare complications of neonatal gonococcal infection.
Localized gonococcal infection of the scalp can result from fetal monitoring through scalp electrodes. Detection of gonococcal
infection in neonates who have sepsis, arthritis, meningitis, or scalp abscesses requires cultures of blood, CSF, and joint aspirate
on chocolate agar. Specimens obtained from the conjunctiva, vagina, oropharynx, and rectum that are cultured on gonococcal
selective medium are useful for identifying the primary site(s) of infection, especially if inflammation is present. Positive Gram-
stained smears of exudate, CSF, or joint aspirate provide a presumptive basis for initiating treatment for N. gonorrhoeae.
Diagnoses based on Gram-stained smears or presumptive identification of cultures should be confirmed with definitive tests on
culture isolates.
Recommended Regimen
Ceftriaxone 25--50 mg/kg/day IV or IM in a single daily dose for 7 days, with a duration of 10--14 days, if meningitis is
documented
OR
Cefotaxime 25 mg/kg IV or IM every 12 hours for 7 days, with a duration of 10--14 days, if meningitis is documented.
Prophylactic Treatment for Infants Whose Mothers Have Gonococcal Infection
Infants born to mothers who have untreated gonorrhea are at high risk for infection.
Recommended Regimen in the Absence of Signs of Gonococcal Infection
Ceftriaxone 25--50 mg/kg IV or IM, not to exceed 125 mg, in a single dose.
Other Management Considerations
Both mother and infant should be tested for chlamydial infection.
Follow-Up
Follow-up examination is not required.
Management of Mothers and Their Sex Partners
The mothers of infants who have gonococcal infection and the mothers' sex partners should be evaluated and treated according
to the recommendations for treatment of gonococcal infections in adults (see Gonococcal Infection).
Gonococcal Infections Among Children
Sexual abuse is the most frequent cause of gonococcal infection in pre-adolescent children (see Sexual Assault or Abuse of
Children). Vaginitis is the most common manifestation of gonococcal infection in preadolescent girls. PID following vaginal
infection is probably less common in children than among adults. Among sexually abused children, anorectal and pharyngeal
infections with N. gonorrhoeae are common and frequently asymptomatic.
Diagnostic Considerations
Because of the legal implications of a diagnosis of N. gonorrhoeae infection in a child, only standard culture procedures for the
isolation of N. gonorrhoeae should be used for children. Nonculture gonococcal tests for gonococci (e.g., Gram-stained smear,
DNA probes, EIA, and NAAT tests) should not be used alone; none of these tests have been approved by FDA for use with
specimens obtained from the oropharynx, rectum, or genital tract of children. Specimens from the vagina, urethra, pharynx, or
rectum should be streaked onto selective media for isolation of N. gonorrhoeae, and all presumptive isolates of N. gonorrhoeae
should be identified definitively by at least two tests that involve different principles (e.g., biochemical, enzyme substrate, or
serologic). Isolates should be preserved to enable additional or repeated testing.
Recommended Regimens for Children Who Weigh ≥45 kg
Treat with one of the regimens recommended for adults (see Gonococcal Infections).
NOTE: Fluoroquinolones have not been recommended for persons aged <18 years because they have damaged articular
cartilage in young animals. However, no such joint damage clearly attributable to quinolone therapy has been observed in
children, even in those receiving multiple-dose regimens.
Recommended Regimens for Children Who Weigh <45 kg and Who Have Uncomplicated Gonococcal Vulvovaginitis, Cervicitis,
Urethritis, Pharyngitis, or Proctitis
Ceftriaxone 125 mg IM in a single dose.
Alternative Regimen
Spectinomycin 40 mg/kg (maximum dose: 2 g) IM in a single dose may be used, but this therapy is unreliable for treatment of
pharyngeal infections. Some specialists use cefixime to treat gonococcal infections in children because it can be administered
orally; however, no reports have been published concerning the safety or effectiveness of cefixime used for this purpose.
Recommended Regimen for Children Who Weigh <45 kg and Who Have Bacteremia or Arthritis
Ceftriaxone 50 mg/kg (maximum dose: 1 g) IM or IV in a single dose daily for 7 days.
Recommended Regimen for Children Who Weigh ≥45 kg and Who Have Bacteremia or Arthritis
Ceftriaxone 50 mg/kg IM or IV in a single dose daily for 7 days.
Follow-Up
Follow-up cultures are unnecessary if ceftriaxone is used. If spectinomycin is used to treat pharyngitis, a follow-up culture is
necessary to ensure that treatment was effective.
Other Management Considerations
Only parenteral cephalosporins are recommended for use in children. Ceftriaxone is approved for all gonococcal infections in
children; cefotaxime is approved for gonococcal ophthalmia only. Oral cephalosporins used for treatment of gonococcal infections
in children have not been adequately evaluated.
All children who have gonococcal infections should be evaluated for coinfection with syphilis and C. trachomatis. (For a
discussion of concerns regarding sexual assault, refer to Sexual Assault or Abuse of Children.)
Ophthalmia Neonatorum Prophylaxis
To prevent gonococcal ophthalmia neonatorum, a prophylactic agent should be instilled into the eyes of all newborn infants; this
procedure is required by law in most states. All of the recommended prophylactic regimens in this section prevent gonococcal
ophthalmia. However, the efficacy of these preparations in preventing chlamydial ophthalmia is less clear, and they do not
eliminate nasopharyngeal colonization by C. trachomatis. The diagnosis and treatment of gonococcal and chlamydial infections in
pregnant women is the best method for preventing neonatal gonococcal and chlamydial disease. Not all women, however,
receive prenatal care. Ocular prophylaxis is warranted because it can prevent sight-threatening gonococcal ophthalmia and
because it is safe, easy to administer, and inexpensive.
Prophylaxis
Recommended Regimens
Silver nitrate (1%) aqueous solution in a single application,
OR
Erythromycin (0.5%) ophthalmic ointment in a single application,
OR
Tetracycline ophthalmic ointment (1%) in a single application.
The availability of silver nitrate in the United States may be limited.
One of these recommended preparations should be instilled into both eyes of every neonate as soon as possible after delivery.
If prophylaxis is delayed (i.e., not administered in the delivery room), a monitoring system should be established to ensure that
all infants receive prophylaxis. All infants should be administered ocular prophylaxis, regardless of whether they are delivered
vaginally or by cesarean section. Single-use tubes or ampules are preferable to multiple-use tubes. Bacitracin is not effective.
Use of povidone iodine has not been studied adequately.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=180593
http://www.cdc.gov/std/Gonorrhea/default.htm
http://www.cdc.gov/STD/treatment/TOC2002TG.htm STD treatment Guildline